USA –
SAN DIEGO, CA, DERMALA has closed a $6.73 million Series A financing co-led by Johnson & Johnson Innovation and True Wealth Ventures.
DERMALA, a consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, has closed a $6.73 million Series A financing.
The Series A financing was co-led by Johnson & Johnson Innovation – JJDC, Inc. and True Wealth Ventures. Seventure Partners, investing via their Health for Life Capital Funds, and Cove Fund also joined the financing round.
DERMALA, Inc. is a privately-held consumer dermatology company leveraging scientific understanding of the human microbiome to develop novel solutions for acne and other skin conditions. The company's #FOBO (Fear of Breaking Out) Kit, a personalized microbiome-based solution for acne, combines patent-pending topical acne treatments with oral supplements and a proprietary DERMALA Acne Tracker app that customers use to track their skin health.
Dermala
